Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals Ltd (ASX: CUV)
Latest News
Healthcare Shares
Why did this ASX 200 healthcare share rocket 16% today?
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
ASX 200 midday update: Magellan rebounds, Crown's takeover boost
Share Market News
3 beaten up shares you might be surprised to learn are still part of the ASX 200
Share Market News
ASX 200 (ASX:XJO) midday update: Magellan jumps on buyback news, travel shares take off
Share Gainers
Why Clinuvel, Dicker Data, Healius, and Uniti shares are rising today
Healthcare Shares
Why is the Clinuvel (ASX:CUV) share price zooming 6% higher today?
Share Market News
Why BHP, Clinuvel, Latitude, and Peet shares are pushing higher
Share Market News
ASX 200 (ASX:XJO) midday update: Afterpay sinks again, BHP and Rio rise
Share Fallers
These were the worst performing ASX 200 shares last week
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
05 Sep 2024 | $0.0500 | 100.00% | Final | 20 Sep 2024 |
05 Sep 2023 | $0.0500 | 100.00% | Final | 20 Sep 2023 |
06 Sep 2022 | $0.0400 | 100.00% | Final | 21 Sep 2022 |
02 Sep 2021 | $0.0250 | 0.00% | Final | 17 Sep 2021 |
03 Sep 2020 | $0.0250 | 0.00% | Final | 18 Sep 2020 |
04 Sep 2019 | $0.0250 | 0.00% | Final | 19 Sep 2019 |
21 Sep 2018 | $0.0200 | 0.00% | Final | 08 Oct 2018 |
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
CUV Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Dec 2024 | $12.15 | $0.04 | 0.33% | 116,245 | $12.05 | $12.30 | $12.02 |
23 Dec 2024 | $12.11 | $0.32 | 2.71% | 152,659 | $11.79 | $12.11 | $11.73 |
20 Dec 2024 | $11.79 | $-0.15 | -1.26% | 121,073 | $12.00 | $12.00 | $11.72 |
19 Dec 2024 | $11.94 | $-0.06 | -0.50% | 140,437 | $11.87 | $12.07 | $11.76 |
18 Dec 2024 | $12.00 | $-0.23 | -1.88% | 185,171 | $12.25 | $12.47 | $11.96 |
17 Dec 2024 | $12.23 | $0.08 | 0.66% | 118,338 | $12.17 | $12.50 | $12.17 |
16 Dec 2024 | $12.15 | $0.02 | 0.16% | 223,999 | $12.10 | $12.30 | $11.85 |
13 Dec 2024 | $12.13 | $-0.32 | -2.57% | 122,183 | $12.42 | $12.42 | $12.12 |
12 Dec 2024 | $12.45 | $-0.20 | -1.58% | 69,432 | $12.65 | $12.84 | $12.43 |
11 Dec 2024 | $12.65 | $-0.09 | -0.71% | 180,133 | $12.70 | $13.04 | $12.64 |
10 Dec 2024 | $12.74 | $0.33 | 2.66% | 142,840 | $12.30 | $12.80 | $12.19 |
09 Dec 2024 | $12.41 | $-0.27 | -2.13% | 143,526 | $12.66 | $12.85 | $12.32 |
06 Dec 2024 | $12.68 | $-0.42 | -3.21% | 117,652 | $13.00 | $13.00 | $12.63 |
05 Dec 2024 | $13.10 | $0.14 | 1.08% | 187,730 | $12.90 | $13.30 | $12.90 |
04 Dec 2024 | $12.96 | $0.00 | 0.00% | 153,725 | $12.90 | $12.96 | $12.56 |
03 Dec 2024 | $12.96 | $-0.08 | -0.61% | 62,453 | $12.97 | $13.09 | $12.87 |
02 Dec 2024 | $13.04 | $-0.11 | -0.84% | 78,884 | $13.23 | $13.44 | $12.95 |
29 Nov 2024 | $13.15 | $0.06 | 0.46% | 61,470 | $13.10 | $13.20 | $12.97 |
28 Nov 2024 | $13.09 | $0.05 | 0.38% | 82,827 | $13.09 | $13.34 | $12.95 |
27 Nov 2024 | $13.04 | $-0.04 | -0.31% | 68,534 | $13.08 | $13.12 | $12.90 |
26 Nov 2024 | $13.08 | $0.17 | 1.32% | 73,811 | $12.95 | $13.11 | $12.87 |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mrs Susan (Sue) Smith | Non-Executive Director | Sep 2019 |
Mrs Smith manages an established consultancy business, providing advisory services to a range of healthcare organisations, investors, and boards of directors. She has led a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Mrs Smith's specific expertise is in the implementation of operational strategies within complex and acute care environments, and in the interaction with healthcare authorities and UK regulators. Her most recent role was as the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practising physicians within the UK independent healthcare sector.
|
Dr Philippe J Wolgen | Chief Executive OfficerManaging Director | Dec 2005 |
Dr Wolgen's leadership led to a long-term strategy for CLINUVEL. The product SCENESSE was reformulated, its medical application identified, European marketing authorisation was obtained in 2014 and systems were established to self-distribute the prescriptive product in the European Economic Area from June 2016. Dr Wolgen oversaw the submission of the scientific dossier to the US Food & Drug Administration (FDA) under a New Drug Application, which was approved in October 2019.
|
Dr Karen Agersborg | Non-Executive Director | Jan 2018 |
Dr Agersborg has diverse and practice experience in Pennsylvania and New Jersey, USA. She is Board Certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism and holds specific expertise on the class of melanocortins. Her career has included inpatient, outpatient, and hospitalist positions across several prominent medical institutions. Dr Agersborg had career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories).
|
Dr Jeffrey Rosenfeld | Non-Executive ChairmanNon-Executive Director | Nov 2019 |
Prof Rosenfeld is a neurosurgeon with experience in senior healthcare and medical research executive roles and career in the Australian Army. He is a retired Major General and a former Surgeon General, Australian Defence Force-Reserves. He has served on eight deployments to Rwanda, Iraq, Solomon Islands, Bougainville, and East Timor. He was the Founding Director of Monash University Institute of Medical Engineering (MIME)-Melbourne. He is developing a bionic vision device to restore vision in people without eyesight, and he is also an adviser in brain injury research. He is also member of the Risk Committee.
|
Mr Matthew William Pringle | Non-Executive Director | Sep 2024 |
Mr Pringle has experience in corporate finance, audit and assurance, governance and strategy, including over 25 years experience as a Partner at Pitcher Partners. His roles with Pitcher Partners included leading the corporate finance practice group, senior audit partner and leading the corporate governance and board advisory practice area.He is a director of Navalo Financial Services Group Limited, Hypersonix Launch Systems Limited, and the not-for-profit Anglicare Victoria.
|
Dr Pearl E Grimes | Non-Executive Director | Sep 2024 |
Dr Grimes is a dermatologist and a leading international authority on vitiligo and pigmentation disorders. She is the Founder and Director of the Vitiligo and Pigmentation Institute of Southern California where she treats patients from all over the world. Dr Grimes is also the director of the Grimes Institute for Medical and Aesthetic Dermatology, where she expertly treats a range of dermatologic health and aesthetic concerns in patients of all ethnicities and skin types. Dr Grimes also serves as a Clinical Professor of Dermatology at the David Geffen School of Medicine at UCLA and Chief Dermatologist for Versicolor Technologies.
|
Mr Guy van Dievoet | Non-Executive Director | Sep 2024 |
Mr van Dievoet has experience in investment banking, specialising in M&A. In this capacity he has worked for financial institutions, including the Merchant bank of IndoSuez in Belgium, ABN-AMRO, Bank BNP Group, and as executive-director for MeesPierson. Over the years he has provided strategic support on corporate growth, structuring and buy-build approaches, and assisted companies listing on the Brussels and Amsterdam Stock Exchanges (EuroNext).
|
Ms Claire Newstead-Sinclair | Company Secretary | Aug 2024 |
-
|
Darren Keamy | CFO & Company Secretary |
-
|
|
Peter Vaughan | Chief Financial Officer |
-
|
|
Lachlan Hay | Chief Operations Officer |
-
|
|
Dennis Wright | Chief Scientific Officer |
-
|
|
Claire Newstead-Sinclair | Company Secretary |
-
|
|
Linda Teng | Director of North American Operations |
-
|
|
Emilie Rodenburger | Director Global Clinical Affairs |
-
|
|
Malcolm Bull | Head of Australian Operations and Investor Relations |
-
|
|
Azza Hamila | Head of Quality Assurance and Drug Safety |
-
|
|
Rose Quadbeck-Diel | Snr VP Regulatory Affairs |
-
|
|
Antonella Colucci | VP Commercial Affairs |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Ltd | 10,225,972 | 20.42% |
BNP Paribas Nominees Pty Ltd ACF (Clearstream) | 5,685,193 | 11.35% |
BNP Paribas Nominees Pty Ltd | 4,988,645 | 9.96% |
J P Morgan Nominees Australia Pty Limited | 3,629,550 | 7.25% |
Dr Philippe Jacques Wolgen | 3,425,222 | 6.84% |
Citicorp Nominees Pty Limited | 3,416,310 | 6.82% |
Ender 1 LLC | 2,590,824 | 5.17% |
BNP Paribas Nominees Pty Ltd (IB AU Noms Retail Client) | 2,207,904 | 4.41% |
HSBC Custody Nominees (Australia) Ltd A/C2 | 922,480 | 1.84% |
Emilino Group Pty Ltd (Emilino Super Fund) | 601,447 | 1.20% |
National Nominees Limited | 548,778 | 1.10% |
Mr Darren Michael Keamy | 362,890 | 0.72% |
Dr Mark Edwin Badcock | 346,772 | 0.69% |
Mr David William Trevorrow | 229,600 | 0.46% |
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 229,044 | 0.46% |
Dr Dennis Wright | 188,812 | 0.38% |
Mr David John Lewis | 185,000 | 0.38% |
Mr Trent Sheldon Redding | 177,370 | 0.35% |
Rusty Hammer Pty Ltd (Archipelago Holdings SF A/C) | 150,722 | 0.30% |
Mr Simon John Bown | 146,000 | 0.29% |